BELLUS HEALTH INC (BLU) Stock Price, Quote, News and Overview
NASDAQ:BLU - Nasdaq - CA07987C2040 - Common Stock - Currency: USD
BLU Quote, Performance and Key Statistics
14.74
0 (0%)
The current stock price of BLU is 14.74 USD. In the past month the price increased by 1.24%. In the past year, price increased by 58.49%.
BLU Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About BLU
Company Profile
BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. The company is headquartered in Laval, Quebec and currently employs 74 full-time employees. The company went IPO on 2000-06-22. The firm's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The firm has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The firm is focused on initiating Phase III program. The firm is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.
Company Info
BELLUS HEALTH INC
275 Armand-Frappier Blvd
Laval QUEBEC H7V 4A7 CA
CEO: Roberto Bellini
Employees: 74
Company Website: https://bellushealth.com/
Phone: 14506804500.0
BELLUS HEALTH INC / BLU FAQ
What is the stock price of BELLUS HEALTH INC today?
The current stock price of BLU is 14.74 USD.
What is the ticker symbol for BELLUS HEALTH INC stock?
The exchange symbol of BELLUS HEALTH INC is BLU and it is listed on the Nasdaq exchange.
On which exchange is BLU stock listed?
BLU stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BELLUS HEALTH INC stock?
10 analysts have analysed BLU and the average price target is 15.39 USD. This implies a price increase of 4.44% is expected in the next year compared to the current price of 14.74. Check the BELLUS HEALTH INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BELLUS HEALTH INC worth?
BELLUS HEALTH INC (BLU) has a market capitalization of 1.87B USD. This makes BLU a Small Cap stock.
How many employees does BELLUS HEALTH INC have?
BELLUS HEALTH INC (BLU) currently has 74 employees.
What are the support and resistance levels for BELLUS HEALTH INC (BLU) stock?
BELLUS HEALTH INC (BLU) has a support level at 14.7 and a resistance level at 14.75. Check the full technical report for a detailed analysis of BLU support and resistance levels.
Is BELLUS HEALTH INC (BLU) expected to grow?
The Revenue of BELLUS HEALTH INC (BLU) is expected to decline by -35.9% in the next year. Check the estimates tab for more information on the BLU EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BELLUS HEALTH INC (BLU) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BLU, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BLU, evaluating the profitability, health, valuation and growth aspects
- BELLUS HEALTH INC (BLU) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BELLUS HEALTH INC (BLU) Sales and EPS estimates to see what analysts future expectations are.
- BELLUS HEALTH INC (BLU) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BELLUS HEALTH INC (BLU) Insider and Institutional Ownership to learn about the owners and their transactions.
- BELLUS HEALTH INC (BLU) Stock Chart to make your own analysis
- BELLUS HEALTH INC (BLU) Latest news and press-releases to stay up to date.
Does BELLUS HEALTH INC (BLU) stock pay dividends?
BLU does not pay a dividend.
When does BELLUS HEALTH INC (BLU) report earnings?
BELLUS HEALTH INC (BLU) will report earnings on 2023-08-08, after the market close.
What is the Price/Earnings (PE) ratio of BELLUS HEALTH INC (BLU)?
BELLUS HEALTH INC (BLU) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.73).
BLU Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to BLU. When comparing the yearly performance of all stocks, BLU is one of the better performing stocks in the market, outperforming 97.91% of all stocks.
BLU Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to BLU. No worries on liquidiy or solvency for BLU as it has an excellent financial health rating, but there are worries on the profitability.
BLU Financial Highlights
Over the last trailing twelve months BLU reported a non-GAAP Earnings per Share(EPS) of -0.73. The EPS increased by 12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
BLU Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 76% to BLU. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of -27.52% and a revenue growth -35.9% for BLU